Scott C Morgan1,2, Oliver E Holmes3, Julia Craig4, Scott Grimes5, Shawn Malone5,6. 1. Radiation Medicine Program, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada. smorgan@toh.ca. 2. Division of Radiation Oncology, University of Ottawa, Ottawa, ON, Canada. smorgan@toh.ca. 3. Division of Oncology, Memorial University of Newfoundland, St. John's, NL, Canada. 4. Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada. 5. Radiation Medicine Program, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada. 6. Division of Radiation Oncology, University of Ottawa, Ottawa, ON, Canada.
Abstract
BACKGROUND: In patients presenting with metastatic prostate cancer, the role of local therapy is evolving. Two recently reported large-scale randomized trials suggest that radiotherapy (RT) directed at the prostate improves overall survival (OS) in patients with low metastatic burden. We reviewed the experience of prostate RT in this setting at our center. METHODS: The study population consisted of men with newly-diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) referred to a comprehensive cancer center between 2005 and 2015 and treated initially with androgen deprivation therapy. Patients were eligible for inclusion if they received (1) prostate RT with biological effective dose (BED) at least that of a course of 40 Gy in 15 fractions or (2) no prostate RT. The association between receipt of prostate RT and OS was studied. OS was estimated using the Kaplan-Meier method and Cox regression was used to identify factors associated with OS. RESULTS: The cohort consisted of 410 patients, of whom 128 received prostate RT. Median follow-up 61.0 months. On univariate analysis, receipt of prostate RT was associated with improved OS (HR 0.59, 95% CI 0.45-0.77, p = 0.0001). Median OS in those patients receiving prostate RT was 47.4 months versus 26.3 months in those not receiving prostate RT. In a multivariate Cox model, receipt of prostate RT remained associated with improved OS (HR 0.69, 95% CI 0.50-0.94, p = 0.02). In those treated with prostate RT, increasing BED was also associated with improved OS (HR 0.87 per 10 Gy increase, 95% CI 0.76-0.99, p = 0.03). CONCLUSIONS: This cohort represents the largest single-center experience of primary tumor-directed RT in mHSPC reported to date. In this population, receipt of prostate RT was associated with improved OS and the magnitude of the OS benefit was clinically significant. The possibility of an RT dose-response gradient in this setting merits further study.
BACKGROUND: In patients presenting with metastatic prostate cancer, the role of local therapy is evolving. Two recently reported large-scale randomized trials suggest that radiotherapy (RT) directed at the prostate improves overall survival (OS) in patients with low metastatic burden. We reviewed the experience of prostate RT in this setting at our center. METHODS: The study population consisted of men with newly-diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) referred to a comprehensive cancer center between 2005 and 2015 and treated initially with androgen deprivation therapy. Patients were eligible for inclusion if they received (1) prostate RT with biological effective dose (BED) at least that of a course of 40 Gy in 15 fractions or (2) no prostate RT. The association between receipt of prostate RT and OS was studied. OS was estimated using the Kaplan-Meier method and Cox regression was used to identify factors associated with OS. RESULTS: The cohort consisted of 410 patients, of whom 128 received prostate RT. Median follow-up 61.0 months. On univariate analysis, receipt of prostate RT was associated with improved OS (HR 0.59, 95% CI 0.45-0.77, p = 0.0001). Median OS in those patients receiving prostate RT was 47.4 months versus 26.3 months in those not receiving prostate RT. In a multivariate Cox model, receipt of prostate RT remained associated with improved OS (HR 0.69, 95% CI 0.50-0.94, p = 0.02). In those treated with prostate RT, increasing BED was also associated with improved OS (HR 0.87 per 10 Gy increase, 95% CI 0.76-0.99, p = 0.03). CONCLUSIONS: This cohort represents the largest single-center experience of primary tumor-directed RT in mHSPC reported to date. In this population, receipt of prostate RT was associated with improved OS and the magnitude of the OS benefit was clinically significant. The possibility of an RT dose-response gradient in this setting merits further study.
Authors: Liselotte M S Boevé; Maarten C C M Hulshof; André N Vis; Aeilko H Zwinderman; Jos W R Twisk; Wim P J Witjes; Karl P J Delaere; R Jeroen A van Moorselaar; Paul C M S Verhagen; George van Andel Journal: Eur Urol Date: 2018-09-25 Impact factor: 20.096
Authors: Chad G Rusthoven; Bernard L Jones; Thomas W Flaig; E David Crawford; Matthew Koshy; David J Sher; Usama Mahmood; Ronald C Chen; Brian F Chapin; Brian D Kavanagh; Thomas J Pugh Journal: J Clin Oncol Date: 2016-06-20 Impact factor: 44.544
Authors: Raj Satkunasivam; Andre E Kim; Mihir Desai; Mike M Nguyen; David I Quinn; Leslie Ballas; Juan Pablo Lewinger; Mariana C Stern; Ann S Hamilton; Monish Aron; Inderbir S Gill Journal: J Urol Date: 2015-02-21 Impact factor: 7.450
Authors: J L Donovan; F C Hamdy; J A Lane; D E Neal; M Mason; C Metcalfe; E Walsh; J M Blazeby; T J Peters; P Holding; S Bonnington; T Lennon; L Bradshaw; D Cooper; P Herbert; J Howson; A Jones; N Lyons; E Salter; P Thompson; S Tidball; J Blaikie; C Gray; P Bollina; J Catto; A Doble; A Doherty; D Gillatt; R Kockelbergh; H Kynaston; A Paul; P Powell; S Prescott; D J Rosario; E Rowe; M Davis; E L Turner; R M Martin Journal: N Engl J Med Date: 2016-09-14 Impact factor: 91.245
Authors: Martin G Sanda; Rodney L Dunn; Jeff Michalski; Howard M Sandler; Laurel Northouse; Larry Hembroff; Xihong Lin; Thomas K Greenfield; Mark S Litwin; Christopher S Saigal; Arul Mahadevan; Eric Klein; Adam Kibel; Louis L Pisters; Deborah Kuban; Irving Kaplan; David Wood; Jay Ciezki; Nikhil Shah; John T Wei Journal: N Engl J Med Date: 2008-03-20 Impact factor: 91.245
Authors: Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Christopher C Parker; Nicholas D James; Christopher D Brawley; Noel W Clarke; Alex P Hoyle; Adnan Ali; Alastair W S Ritchie; Gerhardt Attard; Simon Chowdhury; William Cross; David P Dearnaley; Silke Gillessen; Clare Gilson; Robert J Jones; Ruth E Langley; Zafar I Malik; Malcolm D Mason; David Matheson; Robin Millman; J Martin Russell; George N Thalmann; Claire L Amos; Roberto Alonzi; Amit Bahl; Alison Birtle; Omar Din; Hassan Douis; Chinnamani Eswar; Joanna Gale; Melissa R Gannon; Sai Jonnada; Sara Khaksar; Jason F Lester; Joe M O'Sullivan; Omi A Parikh; Ian D Pedley; Delia M Pudney; Denise J Sheehan; Narayanan Nair Srihari; Anna T H Tran; Mahesh K B Parmar; Matthew R Sydes Journal: Lancet Date: 2018-10-21 Impact factor: 79.321